The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2017 | Case study: daratumumab in a relapsed patient
Saad Usmani, MD, FACP, from the Levine Cancer Institute, Charlotte, NC, discusses an important case study at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. This patient enrolled on daratumumab therapy after his fifth relapse within 18 months of his diagnosis. He had 17p deletion at the time of diagnosis, and had only partial responses to all therapies given. He had a very fast and profound response to daratumumab, leading to MRD negativity. These results show the importance of clinical observations and the immune profiling of these patients.
